Potential use of human interleukin 2 as an adjunct for the therapy of neoplasia, immunodeficiency and infectious disease.
Experimental and clinical systems have been developed to analyze both the in vitro and in vivo effects of highly purified interleukin 2 (IL2) as a potential therapeutic adjunct for neoplasia, immunodeficiency and infectious disease. Animal models, clinical in vitro studies, as well as preliminary clinical trials of IL2 in vivo show that this lymphokine may provide a necessary signal for the activation of thymus-derived T cells in immunologically-compromised hosts.